Menu

Anheuser-Busch Won’t Fund Controversial NIH Alcohol Study

The company’s announcement comes weeks after enrollment was suspended.

Jun 11, 2018
Shawna Williams

ISTOCK, DEBRAMILLETUpdate (June 18): STAT News reports that NIH has shut down the alcohol study. Lawrence Tabak, the head of a task force charged with examining the study, says, “the nature of the engagement with industry representatives calls into question the impartiality of the process.”


Anheuser-Busch InBev has withdrawn a $15-million funding commitment for a mammoth National Institutes of Health study on the effects of moderate alcohol consumption, The New York Times reports. The company’s announcement, made on Friday (June 8), comes after the planned study drew scrutiny over potential conflicts of interest on the part of NIH, which had courted corporate sponsors with the prospect of producing evidence of health benefits of regular drinking.


See “NIH Turned Down Investigators Who Provoked Ire From Alcohol Industry


The planned $100-million study, administered by the NIH’s National Institute of Alcohol Abuse and Alcoholism (NIAAA) would assign thousands of participants either to have an alcoholic drink every day or abstain, and track their health outcomes and mortality over six years. The New York Times reported in March that in an effort to get beverage makers to pick up most of the tab, NIAAA scientists met with industry leaders and “gave talks strongly suggesting that the study’s results would endorse moderate drinking as healthy.” STAT News later found that a separate funding request from researchers whose work had drawn criticism from industry had been turned down by NIAAA.


Following the revelations, NIH Director Francis Collins announced that the agency was reviewing the process around funding for the trial and would determine whether it should proceed, and that enrollment had been suspended for the time being, The Washington Post reported last month.


Anheuser-Busch announced its decision to withdraw funding in a letter to the Foundation for the National Institutes of Health. According to the Times, the letter concludes, “Unfortunately, recent questions raised around the study could undermine its lasting credibility, which is why we have decided to end our funding.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.